-
GenScript Biotech Expands in Australia with New Sydney Operations and Logistics Center
•
GenScript Biotech Corporation (HKG: 1548), a leading Chinese biotechnology company, has announced the establishment of a new operations site and logistics center in Sydney, Australia. This strategic move highlights GenScript’s commitment to supporting the burgeoning biotechnology sector in Australia. Sydney Facility’s Role in Streamlining OperationsThe new Sydney facility is designed…
-
GenScript Dissolves Merger with CAR-T Specialist Legend Biotech, Reclassifies as Associated Company
•
GenScript Biotech Corporation (HKG: 1548), a comprehensive life science research and application service and product provider based in China, has announced the dissolution of its merger with Legend Biotech Corporation (NASDAQ: LEGN), a specialist in chimeric antigen receptor (CAR) T-cell therapy. The decision to dissolve the merger was influenced by…
-
GenScript Biotech Receives Over USD 410 Million in Milestone Payments for CAR-T Therapy from Janssen Biotech
•
GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced that it has received a total of USD 410 million in milestone payments from Janssen Biotech, a subsidiary of Johnson & Johnson (J&J, NYSE: JNJ). These payments are part of a licensing agreement with its…
-
GenScript Shares Slide on US Congressional Request for FBI Investigation
•
Shares of GenScript Biotechnology Co., Ltd (HKG: 1548), a China-based Contract Development and Manufacturing Organization (CDMO), plummeted over 17% in trading today following a request by a US House of Representatives committee on China for the FBI to investigate the company and its subsidiaries. The committee, led by chair John…
-
GenScript’s Subsidiary Legend Biotech Expands EU Approval for CAR-T Therapy Carvykti
•
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), has secured an expanded indication approval from the European Union for its BCMA-targeted chimeric antigen receptor T cell (CAR-T) therapy, Carvykti (ciltacabtagene autoleucel). The therapy is now approved as a…
-
GenScript Biotech Corporation Reports 34.2% YOY Revenue Growth in 2023 Financial Results
•
China-based GenScript Biotech Corporation (HKG: 1548) has announced its financial results for 2023, reporting revenues of USD 839.5 million for the year, marking a 34.2% year-on-year (YOY) increase. External revenues from non-cell therapy business reached USD 554.5 million, up 8.9% YOY, while cell therapy sales soared to USD 285 million,…
-
Carvykti CAR-T Therapy Sales Reach $157 Million in Q1 2024, Reports GenScript Subsidiary Legend Biotech
•
GenScript Biotech Corporation (HKG: 1548), a leading Contract Research Organization (CRO) based in China, has announced that its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), achieved sales of USD 157 million for its BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy, Carvykti (ciltacabtagene autoleucel), in the first quarter of 2024, which…
-
Legend Biotech’s Carvykti Earns FDA Committee’s Unanimous Recommendation for Expanded Use
•
GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced that its subsidiary Legend Biotech Corporation’s (NASDAQ: LEGN) BCMA-targeted chimeric antigen receptor T cell (CAR-T) therapy, Carvykti (ciltacabtagene autoleucel), has received a recommendation from the US FDA’s Oncologic Drugs Advisory Committee (ODAC). Following a review…
-
Legend Biotech’s Carvykti Earns FDA Committee’s Unanimous Recommendation for Expanded Use
•
GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced that its subsidiary Legend Biotech Corporation’s (NASDAQ: LEGN) BCMA-targeted chimeric antigen receptor T cell (CAR-T) therapy, Carvykti (ciltacabtagene autoleucel), has received a recommendation from the US FDA’s Oncologic Drugs Advisory Committee (ODAC). Following a review…
-
GenScript’s Subsidiary Legend Biotech Gets CHMP Nod for Carvykti Label Expansion in Multiple Myeloma
•
GenScript Biotech Corporation (HKG: 1548), a China-based Contract Research Organization (CRO), has announced that its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the label expansion of its (BCMA)-directed chimeric antigen receptor T…
-
Legend Biotech’s Carvykti Therapy to Include Myeloid Neoplasms Warning in Label Update
•
GenScript Biotech Corporation (HKG: 1548), a China-based Contract Research Organization (CRO), has announced that its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), will update the warning label for its BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy, Carvykti (ciltacabtagene autoleucel), to account for the potential risk of myeloid neoplasms in patients…
-
GenScript Reports $152 Million in Sales for Carvykti as of September 30, 2023
•
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), achieved sales of USD 152 million for its BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy, Carvykti (ciltacabtagene autoleucel), as of September 30, 2023. This represents a year-on-year growth rate…
-
GenScript Biotech’s CAR-T Therapy Carvykti Reports USD 117 Million in Sales
•
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), has reported sales of USD 117 million for its BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy, Carvykti (ciltacabtagene autoleucel), as of June 30, 2023. The sales data, provided by…
-
GenScript Biotech Expands cGMP Manufacturing for Gene and Cell Therapy in Zhenjiang Facility
•
China-based GenScript Biotech Corporation (HKG: 1548) has announced the expansion of its current Good Manufacturing Practice (cGMP) manufacturing capacity at a new facility located in Zhenjiang, Jiangsu province. This move is set to enhance the company’s ability to offer manufacturing services for sgRNA and non-viral DNA payloads, thereby better serving…
-
GenScript’s Legend Biotech Files Type II Variation Application for Carvykti with EMA
•
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), has submitted a Type II variation application to the European Medicines Agency (EMA) for its BCMA-targeted chimeric antigen receptor (CAR) T cell therapy, Carvykti (ciltacabtagene autoleucel). The application is supported…
-
GenScript Biotech’s Legend Biotech Secures Private Placement with Hillhouse Investment
•
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has revealed that its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), is set to conduct a private placement of 692,800 shares at USD 32 per share to LGN Holdings Ltd, a company solely managed by Hillhouse Investment Management, Ltd. This transaction…
-
Luye Pharma’s Boan Biotechnology Partners with GenScript on GenCircle dsDNA Development
•
Shandong Boan Biotechnology Co., Ltd, a controlling subsidiary of China-based Luye Pharma Group (HKG: 2186), has entered into a strategic partnership with GenScript Biotech Corporation (HKG: 1548), a leading Contract Research Organization (CRO). The collaboration aims to develop and manufacture the small circular double-stranded DNA vector GenCircle dsDNA, which is…
-
GenScript Biotech’s Subsidiary Legend Biotech Announces Positive CAR-T Therapy Results
•
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), has filed a 6-K with the US Securities and Exchange Commission and published clinical studies with the European Hematology Association (EHA) regarding its chimeric antigen receptor (CAR)-T therapies. The release…
-
GenScript ProBio Partners with Bio Immunitas for hRPP Platform
•
Nanjing-based GenScript ProBio, a leading biologics Contract Development and Manufacturing Organization (CDMO), has formed a long-term partnership with UK-based Bio Immunitas, a firm built around a proprietary human Recombinant Protein Platform (hRPP). This strategic collaboration aims to accelerate Bio Immunitas’s manufacturing capabilities from the lab to clinic, including IND-enabling CMC…
-
GenScript’s CAR-T Therapy Carvykti Achieves $55M in Sales, Awaits China Approval
•
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that sales of its subsidiary company Legend Biotech Corporation’s (NASDAQ: LEGN) BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy, Carvykti (ciltacabtagene autoleucel), reached USD 55 million as of December 31, 2022. This figure, yet to be independently audited,…
